- Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
- Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
- Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
- Vistagen to Present at the Jefferies Global Healthcare Conference
- Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
More ▼
Key statistics
As of last trade, Vistagen Therapeutics Inc (VTGN:NAQ) traded at 3.87, 137.42% above the 52 week low of 1.63 set on Aug 04, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.90 |
---|---|
High | 3.94 |
Low | 3.84 |
Bid | 3.87 |
Offer | 3.89 |
Previous close | 3.94 |
Average volume | 102.41k |
---|---|
Shares outstanding | 27.06m |
Free float | 26.99m |
P/E (TTM) | -- |
Market cap | 106.60m USD |
EPS (TTM) | -2.12 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 15:51 BST.
More ▼